Want to see JP:4886 full AI Analyst Report?
ASKA Pharmaceutical Holdings Co., Ltd. (4886) AI Stock Analysis
ASKA Pharmaceutical Holdings Co., Ltd.
(TSE/TYO:4886)
ASKA Pharmaceutical's overall score of 72 reflects its strong financial foundation, including a robust balance sheet and improving cash flows, which are positive long-term indicators. However, the stock is currently in a downtrend with bearish technical signals, which tempers near-term optimism. The attractive valuation (low P/E and solid dividend yield) provides a margin of safety. Investors should monitor for a potential technical reversal while acknowledging the company's solid fundamentals.
ASKA Pharmaceutical Holdings Co., Ltd. (4886) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 56.39B
- Dividend Yield
- 3.27%
- Average Volume (3M)
- 73.91K
- Price to Earnings (P/E)
- 12.0
- Beta (1Y)
- 0.41
- Revenue Growth
- ―
- EPS Growth
- -7.20%
- Country
- Japan
- Employees
- 1,611
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
ASKA Pharmaceutical Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the...
How the Company Makes Money
ASKA Pharmaceutical Holdings primarily makes money by earning revenue from the sale of prescription pharmaceuticals produced and/or marketed by its consolidated subsidiaries. Key revenue streams generally include (1) domestic product sales in Japan:...
ASKA Pharmaceutical Holdings Co., Ltd. Financial Statement Overview
Summary
ASKA Pharmaceutical shows steady revenue growth (8.7% in FY2026) and healthy gross margins (~48%). Operating and net margins have moderated but remain positive. The balance sheet is exceptionally strong with minimal debt (debt-to-equity 0.05) and growing equity. Cash flow generation improved significantly, with operating cash flow covering debt 1.9x. Overall financial health is solid, though margin consistency could improve.
Income Statement
78PositiveBalance Sheet
92Very PositiveCash Flow
84Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 70.87B | 71.13B | 64.14B | 62.84B | 60.46B | 56.61B |
| Gross Profit | 33.60B | 34.15B | 31.34B | 30.66B | 28.59B | 26.35B |
| EBITDA | 6.69B | 8.75B | 7.58B | 9.16B | 8.24B | 7.68B |
| Net Income | 4.71B | 5.42B | 5.10B | 7.54B | 4.24B | 4.29B |
Balance Sheet | ||||||
| Total Assets | 109.91B | 112.01B | 103.25B | 93.31B | 87.14B | 83.30B |
| Cash, Cash Equivalents and Short-Term Investments | 7.11B | 11.02B | 11.16B | 17.24B | 17.91B | 17.10B |
| Total Debt | 11.84B | 11.43B | 10.90B | 9.48B | 12.62B | 14.05B |
| Total Liabilities | 32.61B | 35.56B | 34.06B | 31.38B | 32.60B | 34.40B |
| Stockholders Equity | 70.77B | 69.99B | 65.31B | 61.93B | 54.53B | 48.89B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 3.75B | -475.00M | 166.00M | 2.89B | 2.26B |
| Operating Cash Flow | 0 | 6.30B | 2.48B | 1.49B | 3.35B | 2.84B |
| Investing Cash Flow | 0 | -5.75B | -6.12B | 1.71B | -1.13B | 6.74B |
| Financing Cash Flow | 0 | -818.00M | -2.96B | -3.94B | -1.82B | -3.00B |
ASKA Pharmaceutical Holdings Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4886, the sentiment is Negative. The current price of 1957.00 is below the 20-day moving average (MA) of 2011.85, below the 50-day MA of 2055.85, and below the 200-day MA of 2301.07, indicating a bearish trend. The MACD of -18.83 indicates Positive momentum. The RSI at 40.37 is Neutral, neither overbought nor oversold. The STOCH value of 20.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4886.
ASKA Pharmaceutical Holdings Co., Ltd. Peers Comparison
Overall Rating
- JP:488672Outperform
JP:453468Neutral
JP:457767Neutral
JP:452164.9Neutral
JP:455460Neutral
JP:456952Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4886 | 72Outperform | JPY 52.85B | 11.96 | ― | 3.27% | ― | -7.20% |
| JP:4534 | 68Neutral | JPY 111.78B | 12.67 | 6.64% | 2.51% | 14.72% | 52.55% |
| JP:4577 | 67Neutral | JPY 38.17B | 12.15 | ― | 3.02% | -2.83% | 65.69% |
| JP:4521 | 65Neutral | JPY 137.95B | 14.06 | 6.94% | 4.96% | -6.86% | -17.71% |
| JP:4554 | 60Neutral | JPY 48.76B | 15.72 | 6.04% | 2.15% | 20.36% | -5.53% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4569 | 52Neutral | JPY 58.17B | 29.23 | ― | 4.25% | -4.71% | -78.91% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4886 | ASKA Pharmaceutical Holdings Co., Ltd. | 1986.00 | -67.16 | -3.27% | |
| JP:4521 | Kaken Pharmaceutical Co | 3830.00 | 309.93 | 8.80% | |
| JP:4554 | Fuji Pharma Co., Ltd. | 1870.00 | 301.64 | 19.23% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3285.00 | 312.28 | 10.50% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1105.00 | -267.62 | -19.50% | |
| JP:4577 | Daito Pharmaceutical Co., Ltd. | 1323.00 | 116.26 | 9.63% |
ASKA Pharmaceutical Holdings Co., Ltd. Corporate Events
ASKA Pharmaceutical Completes Treasury Share Disposal for Restricted Stock Compensation
ASKA Pharmaceutical Holdings has completed payment procedures for the disposal of 53,600 treasury shares as restricted share remuneration, following a July 13, 2026 board resolution. The ordinary shares were disposed at 2,259 yen per share, for a tot...
ASKA Pharmaceutical’s Q1 Profit Slumps, Full‑Year Outlook Steady
ASKA Pharmaceutical Holdings reported first‑quarter consolidated net sales of 17.3 billion yen, down 1.5 percent year on year, as National Health Insurance drug price revisions and weakness in its overseas business weighed on revenue. The compa...
ASKA Pharmaceutical Posts Weaker Q1 Earnings but Holds Dividend and Full-Year Guidance
ASKA Pharmaceutical Holdings reported first-quarter FY2026 net sales of ¥17.38 billion, down 1.5% year on year, with operating profit falling 51.4% to ¥711 million and profit attributable to owners dropping 57.5% to ¥533 million. Despi...
ASKA Pharma to Grant Restricted Treasury Shares via Employee Share Plan
ASKA Pharmaceutical Holdings has approved the disposal of 22,198 treasury shares as restricted stock to its Employee Shareholding Association, with a disposal price of 2,259 yen per share and a maximum total value of about 50.1 million yen. The final...
ASKA Pharma Uses Treasury Shares to Expand Performance-Linked Restricted Stock Plan
ASKA Pharmaceutical Holdings has approved the disposal of 53,600 treasury shares, worth about 121 million yen, to be granted as restricted stock to directors and officers across the parent company and its subsidiaries. The allocation covers both insi...
ASKA Pharma Wins Broad Shareholder Backing, Adopts Anti-Takeover Safeguard
ASKA Pharmaceutical Holdings reported that all 11 company-sponsored proposals at its fifth ordinary general meeting of shareholders were approved, while a shareholder-backed slate of two board candidates was voted down. The approvals covered appropri...
ASKA Pharma revamps restricted share pay as it shifts to new governance structure
ASKA Pharmaceutical Holdings has resolved to revise its restricted share remuneration system for internal board members and introduce a similar scheme for outside directors, aligning compensation more closely with shareholder interests and long-term...
ASKA Pharmaceutical switches auditors to EY ShinNihon to support global expansion
ASKA Pharmaceutical Holdings will change its accounting auditor from Seiyo Audit Corporation to Ernst & Young ShinNihon LLC, pending approval at its June 24, 2026 shareholders meeting. The move comes after Seiyo’s long tenure since 2011 and...
ASKA Seeks Shareholder Mandate for Defense Against Potential Dalton-Led Takeover Move
ASKA Pharmaceutical Holdings’ board has decided to seek shareholder approval at its June 24, 2026 annual general meeting to implement defensive countermeasures if a consortium led by Dalton Investments proceeds with a large-scale, non-compliant...
ASKA Pharma to Embed Corporate Philosophy and Shift to Audit Committee Governance
ASKA Pharmaceutical Holdings will seek shareholder approval on June 24, 2026, to amend its Articles of Incorporation by formally embedding its longstanding corporate philosophy of contributing to health and society through innovative products, signal...
ASKA Pharma Corrects Pension Accounting Data Without Affecting FY2026 Earnings
ASKA Pharmaceutical Holdings has corrected certain items in its consolidated financial results for the fiscal year ended March 31, 2026, after identifying deficiencies in underlying data used for retirement benefit accounting. The revisions, triggere...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026